Products for Research Use Only

Necrostatin-1

CAT: 0804-HY-15760-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15760-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Necrostatin-1 (Nec-1) is a potent and cross the blood-brain barrier necroptosis inhibitor with an EC50 of 490 nM in Jurkat cells. Necrostatin-1 inhibits RIP1 kinase (EC50=182 nM) . Necrostatin-1 is also an IDO inhibitor[1].
CAS Number
4311-88-0
Product Name Alternative
Nec-1
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; Ferroptosis; Indoleamine 2,3-Dioxygenase (IDO) ; Necroptosis; RIP kinase
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Necrostatin-1.html
Purity
99.89
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(C(CC1=CNC2=C1C=CC=C2)N3)N(C)C3=S
Molecular Formula
C13H13N3OS
Molecular Weight
259.33
Precautions
H302, H315, H319, H335
References & Citations
[1]Degterev A, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005 Jul;1 (2) :112-9.|[2]Linkermann A, et al. The RIP1-kinase inhibitor necrostatin-1 prevents osmotic nephrosis and contrast-induced AKI in mice. J Am Soc Nephrol. 2013 Oct;24 (10) :1545-57.|[3]Huang C, et al. Shikonin kills glioma cells through necroptosis mediated by RIP-1. PLoS One. 2013 Jun 28;8 (6) :e66326.|[4]Feyen D, et al. Increasing short-term cardiomyocyte progenitor cell (CMPC) survival by necrostatin-1 did not further preserve cardiac function. Cardiovasc Res. 2013 Jul 1;99 (1) :83-91.|[5]Zhou K, et al. RIP1-RIP3-DRP1 pathway regulates NLRP3 inflammasome activation following subarachnoid hemorrhage. Exp Neurol. 2017 Sep;295:116-124.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Alternative Products

Popular Products